# Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B

> **NCT04182321** · NA · COMPLETED · sponsor: **Fu-Sheng Wang** · enrollment: 60 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Metformin & Entecavir
- **DRUG:** Placebo & Entecavir

## Key facts

- **NCT ID:** NCT04182321
- **Lead sponsor:** Fu-Sheng Wang
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-13
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-09-13
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182321, "Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04182321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*